Massachusetts-based heart support technologies major, Abiomed Inc. (ABMD) recently received 510(k) approval from the U.S. Food and Drug Administration (:FDA) for its new Impella product dubbed Impella ...

Abiomed, Inc. ABMD recently announced the receipt of FDA Pre-Market Approval (PMA) for its Impella CPheart pump with SmartAssist, featuring an optical sensor. This will broaden the portfolio of its ...

WASHINGTON, DC—Patients with STEMI complicated by severe cardiogenic shock do not derive a benefit from routine use of the Impella CP mechanical circulatory support (MCS) device during primary PCI, ...

CHICAGO, IL—In a pilot study, unloading the left ventricle with the Impella CP mechanical circulatory support device (Abiomed) and delaying PCI by 30 minutes appeared to be feasible and safe in ...

Danvers, MA-based ABIOMED, Inc.ABMD, a leading medical product developer, announced the expanded U.S. FDA pre-market approval (PMA) for the usage of Impella CP heart pump. The heart pump is used for ...

SAN FRANCISCO--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and ...

Use of a microaxial flow pump (Impella CP) with standard care led to a lower risk for death than standard care alone in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic ...

BOSTON--(BUSINESS WIRE)--Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in ...

Massachusetts-based heart support technologies major, Abiomed Inc. ( ABMD) recently received 510(k) approval from the U.S. Food and Drug Administration (FDA) for its new Impella product dubbed Impella ...

Massachusetts-based heart support technologies major, Abiomed Inc. (ABMD) recently received 510(k) approval from the U.S. Food and Drug Administration (:FDA) for its new Impella product dubbed Impella ...